

03<sup>rd</sup> November, 2017

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Sub: Compliances under Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for half year ended 30<sup>th</sup> September, 2017**

In continuation to our letter dated 03<sup>rd</sup> November, 2017, submitting the Financial Results of the Company for the quarter and half year ended on 30<sup>th</sup> September, 2017, please find below the NCD payment Schedule and credit rating as required under Regulation 52 (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) with respect to Company’s privately placed secured non convertible debentures:

Sr No	ISIN Number	Previous due date		Next due date		Credit Rating
		Principal	Interest	Principal	Interest	
1	INE685A07025	-	23-Jun-17	22-Jun-18	22-Jun-18	ICRA AA with Positive Outlook
2	INE685A07033	-	23-Jun-17	24-Jun-19	22-Jun-18	ICRA AA with Positive Outlook
3	INE685A07041	-	23-Jun-17	24-Jun-20	22-Jun-18	ICRA AA with Positive Outlook
4	INE685A07058	-	27-Jun-17	26-Mar-18	26-Mar-18	ICRA AA with Positive Outlook
5	INE685A07066	-	-	13-Dec-18	13-Dec-17	ICRA AA with Positive Outlook
6	INE685A07074	-	-	28-Dec-18	29-Dec-17	ICRA AA with Positive Outlook

Interest has been paid on or before the due dates.

Further, please find enclosed herewith the certificate received from IDBI Trusteeship Services Limited, Debenture Trustee as per Regulation 52(5) of Listing Regulations stating that they have taken note of the relevant information pertaining to the half year ended on 30<sup>th</sup> September, 2017.



**TORRENT PHARMACEUTICALS LIMITED**

CIN : L24230GJ1972PLC002126

The above is for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY

No. 6144/ITSL/OPR/2017-18

November 3, 2017

To,

**Torrent Pharmaceuticals Limited**

Torrent House,

Off Ashram Road,

Ahmedabad – 380 009

Kind Attn: Company Secretary

Dear Sir,

**Sub: Letter of Debenture Trustee pursuant to Regulation 52 (5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended September 30, 2017**

This has reference to the privately placed Secured/Unsecured, Non-Convertible Debentures issued by **Torrent Pharmaceuticals Limited** ("Issuer") wherein IDBI Trusteeship Services Limited is acting as the Debenture Trustee and listed on the National Stock Exchange of India Ltd. (NSE) and/or Bombay Stock Exchange (BSE) ("**Listed Debt Securities**").


Pursuant to Regulation 52(4) read with Regulation 52 (5) of the SEBI (Listing Obligations and Disclosure Requirements) 2015, the Issuer is required to submit the documents required there along with its half yearly/annual financial results to the Stock Exchange, with a letter of the Debenture Trustee (IDBI Trusteeship Services Limited) that the Debenture Trustee has noted the contents furnished by the Issuer as per Regulation 52(4).

In pursuance thereof, we hereby confirm that we have received the aforesaid information through your letter dated November 03, 2017 and we have noted the contents provided therein.

Thanking you,

Yours faithfully

For **IDBI Trusteeship Services Limited**

  
Authorised Signatory



